Close Menu

NEW YORK – The US Food and Drug Administration approved encorafenib (Pfizer/Array BioPharma's Braftovi) on Thursday in combination with cetuximab (Eli Lilly's Erbitux) for BRAF V600E-Mutated metastatic colorectal patients. The drug combination is intended for those who have received prior therapy and have their BRAF mutation status detected by an FDA-approved test.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.